Cardiac manifestations of eosinophilic granulomatosis with polyangiitis from a single-center cohort in China: clinical features and associated factors
| Autor: | Yongtai Liu, Xiaofeng Zeng, Li Wang, Zhaocui Zhang, Fengchun Zhang, Mengtao Li, Ling Guo, Suying Liu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
030203 arthritis & rheumatology
associated factors medicine.medical_specialty cardiac manifestations treatment business.industry lcsh:RM1-950 Medicine (miscellaneous) 030204 cardiovascular system & hematology Single Center medicine.disease outcomes Dermatology eosinophilic granulomatosis with polyangiitis 03 medical and health sciences lcsh:Therapeutics. Pharmacology 0302 clinical medicine Cohort Eosinophilic cardiac involvement Medicine business Granulomatosis with polyangiitis Original Research |
| Zdroj: | Therapeutic Advances in Chronic Disease Therapeutic Advances in Chronic Disease, Vol 12 (2021) |
| ISSN: | 2040-6223 |
| Popis: | Background: Cardiac manifestations are common and life-threatening in eosinophilic granulomatosis with polyangiitis (EGPA), which remains poorly studied in China. We aim to investigate its clinical features, associated factors, treatment, and outcomes. Methods: We reviewed the clinical records of 110 EGPA patients and examined the independent factors associated with cardiac manifestations using multivariate logistic regression. Receiver operating characteristic curves determined the cut-off values, and survival was calculated via Kaplan–Meier curves. Results: Cardiac involvement was present in 36.4% (40/110) of EGPA patients, which mainly manifested as pericardial effusion (16.4%, 18/110), myocardial involvement (13.6%, 15/110), and heart failure (8.2%, 9/110). The mean age was 42.1 ± 14.23 years with no female/male predominance. Compared with the cardiac-unaffected group, the cardiac-affected group showed a lower rate of biopsy-proved vasculitis (0% versus 20%, p = 0.002). The eosinophil count [odds ratio (OR) = 1.142, 95% confidence interval (CI) 1.029–1.267] was independently associated with cardiac manifestations in EGPA, with a cut-off value of 3.66 × 109/L [area under the curve (AUC) = 0.692, p = 0.001]. Regarding treatment, the cardiac-affected group displayed a higher ratio of glucocorticoid pulse combined with intravenous cyclophosphamide (CYC-IV) (40% versus 21.4%, p = 0.037), and intravenous immunoglobulin combined with glucocorticoid plus CYC-IV (17.5% versus 4.3%, p = 0.035) than the control group. Outcomes ( p = 0.131) and survival ( p = 0.1972) were not significantly different between the groups. Conclusion: In this single-center Chinese EGPA cohort, cardiac manifestations are observed in 36.4% of patients, which primarily presents as myocardial involvement, pericardial effusion, and heart failure, independently associated with eosinophil count. Glucocorticoid combined with cyclophosphamide is the treatment cornerstone for EGPA patients with cardiac manifestations. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|